Drug Abuse During the COVID-19 Pandemic.

Stress, Psychological Clinical Trial

Official title:

Readiness for a Pandemic, and Factors Associated With Substance Abuse During the COVID-19 Pandemic - A Cross-Sectional Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04811352
• Other study ID #: Uso_drogas
• Status: Completed
• Start date: March 1, 2021
• Est. completion date: June 1, 2021

Study information

• Verified date: September 2023
• Source: Instituto Mexicano del Seguro Social
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The pandemic we live through has put various sectors of the medical system and its tributaries to the test. The accumulation of external and internal stress has been completely correlated with the predisposition to psycho-emotional problems and, in turn, to drug use as an immature response for ego protection. That is why the economic, social, and psychological evaluation can help understand the current situation about drug abuse and how to help patients afflicted by it. The added stress of personal problems, work alterations, daily life in a pandemic, economic and varied responsibilities, and the understanding of the pandemic have predisposed and amplified the use of drugs to reduce emotional distress perceived by individuals. The hypothesis of this study is that the increment of stress and a lack of preparation for the pandemic are associated with increased drug abuse.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: June 1, 2021
• Est. primary completion date: May 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• > 18 years old
• Willing to participate in the study
• Patient currently with a paying job

Exclusion Criteria:

• Patients without a paying job

Related Conditions & MeSH terms

• COVID-19
• Stress, Psychological
• Substance Abuse
• Substance-Related Disorders

Locations

Country	Name	City	State
Mexico	Centro Médico Nacional de Occidente	Guadalajara	Jalisco

Sponsors (1)

Lead Sponsor	Collaborator
Instituto Mexicano del Seguro Social

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Behaviour on drug and substance abuse	The survey inquires about the frequency and dosage of numerous substances such as coffee, alcohol, tobacco, and heroin since the pandemic started.	Baseline
Primary	PHQ-9 Score	This inventory will be used to identify the presence and intensity of depressive disorders. The minimum score is 0, and the maximum score is 27.	Baseline
Primary	GAD-7 Score	This questionnaire will be used to evaluate the presence and intensity of anxiety disorders. The minimum score is 0, and the maximum score is 21.	Baseline